News | April 12, 2024
CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Application based on results from the TROPION-Breast01 Phase III trial
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Subscribe To Our Newsletter & Stay Updated
